The prognosis of breast cancer patients with bone metastasis could be potentially estimated based on blood routine test and biochemical examination at admission

Abstract

Purpose Due to the poor and unpredictable prognosis of breast cancer (BC) patients with bone metastasis, it is necessary to find convenient and available prognostic predictors. This study aimed to recognize the clinical and prognostic factors related to clinical laboratory examination and to construct a prognostic nomogram for BC bone metastasis. Methods We retrospectively analyzed 32 candidate indicators from clinical features and laboratory examination data of 276 BC patients with bone metastasis. Univariate and multivariate regression analyses were performed to identify significant prognostic factors related to BC with bone metastasis. Nomogram was constructed and estimated by receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis. Results Patients were randomly grouped into training ( n = 197) and validation cohorts ( n = 79). In training cohort, the multivariate regression analysis revealed that age, other organ metastasis sites, serum level of lactate dehydrogenase, globulin, white blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, and monocyte ratio were independent prognostic factors for BC with bone metastasis. The prognostic nomogram in training cohort exhibited areas under the ROC curve (AUCs) of 0.797, 0.782, and 0.794, respectively, for predicting 1-, 3-, and 5-year overall survival. In validation cohort, the nomogram still showed acceptable discrimination ability (AUCs: 0.723, 0.742, and 0.704) and calibration. Conclusion This study constructed a novel prognostic nomogram for BC patients with bone metastasis. It could serve as a potential tool of survival assessment to help individual treatment decision-making for clinicians.

Cost-effective prognostic evaluation of breast cancer: using a STAR nomogram model based on routine blood tests

“…Some hematological markers, such as inflammatory index and red blood cell distribution width, have obvious advantages in predicting prognosis ( 20 – 22 ). Inflammation plays a crucial regulatory role in the development of breast cancer ( 23 ), and hematological biomarkers can provide valuable clues about pathophysiological changes ( 24 , 25 ). Research has shown that a higher lymphocyte proportion is positively correlated with a favorable prognosis ( 26 ), whereas a lower percentage of eosinophils ( 27 ), higher red blood cell distribution width ( 28 ), and higher platelet large cell ratio ( 29 ) are associated with a poorer prognosis.…”

Thromboelastogram and coagulation function index: relevance for female breast cancer

“…In this sense, cancer-related thrombosis has become an important basis for the prediction and clinical analysis of breast cancer ( 3 ). A number of blood parameters related to transfusion technology [e.g., TEG ( 34 ), routine blood test ( 35 ), and PLT count ( 36 )] are important in providing effective information during the whole procedure of medical interventions, including tumor screening ( 37 ), risk assessment ( 38 ), and inpatient ( 39 ) and outpatient prevention ( 40 ). Research shows that venous thrombosis is one of the common causes of death in patients with breast cancer ( 41 ).…”